secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001104659-23-035170
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis CCO Nicole Sweeny departs; cash runway extended to Q2 2024 via restructuring
--------------------------------------------------------------------------------

- Nicole Sweeny, Chief Commercial Officer, to depart effective March 31, 2023; no dispute or disagreement cited.
- Separation agreement provides 9 months base salary ($337,500) plus COBRA premium subsidy.
- Company refocuses on ulixacaltamide end-of-Phase-2 FDA meeting, PRAX-562 and PRAX-222 readouts.
- Realigned expenses and headcount expected to extend cash runway into Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/0001104659-23-035170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/tm239181d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer